0.094
0.00 (2.07%)
| Penutupan Terdahulu | 0.092 |
| Buka | 0.092 |
| Jumlah Dagangan | 4,500,385 |
| Purata Dagangan (3B) | 15,417,863 |
| Modal Pasaran | 7,023,986 |
| Harga / Buku (P/B) | 0.510 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Mar 2025 - 4 Apr 2025 |
| EPS Cair (TTM) | -879.72 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.92% |
| Nisbah Semasa (MRQ) | 4.94 |
| Aliran Tunai Operasi (OCF TTM) | -17.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -12.32 M |
| Pulangan Atas Aset (ROA TTM) | -127.31% |
| Pulangan Atas Ekuiti (ROE TTM) | -477.53% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | CNS Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.21% |
| % Dimiliki oleh Institusi | 1.13% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Barrett & Company, Inc. | 31 Mar 2025 | 100 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Jun 2025 | Pengumuman | CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit |
| 16 May 2025 | Pengumuman | CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 13 May 2025 | Pengumuman | CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules |
| 13 May 2025 | Pengumuman | CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 |
| 01 Apr 2025 | Pengumuman | CNS Pharmaceuticals Reports Full Year 2024 Financial Results |
| 25 Mar 2025 | Pengumuman | CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |